

Number 476 • September 2014

Removal of temporary benefits from the Alberta Drug Benefit List (ADBL)

Due to the shortage of Uremol-HC Topical Cream (DIN 00503134) and Uremol-HC Topical Lotion (DIN 00560022), manufactured by Glaxosmithkline, Dermaflex HC 1% Cream (DIN 00681989) and Dermaflex HC 1% Topical Lotion (DIN 00681997), manufactured by Paladin Labs Inc., were added as temporary benefits for the *Alberta Drug Benefit List (ADBL)* as of June 19, 2012.

Glaxosmithkline has advised Alberta Blue Cross that Uremol-HC Topical Cream (DIN 00503134) and Uremol-HC Topical Lotion (DIN 00560022) have now been discontinued. As such, these products will be removed from the *ADBL* in accordance with the *Transitional Period Price Policy* available at https://www.ab.bluecross.ca/dbl/publications.html#pricepolicy.

As a result, Dermaflex HC 1% Cream (DIN 00681989) and Dermaflex HC 1% Topical Lotion (DIN 00681997) will no longer be considered as temporary benefits for the *ADBL* effective **October 31, 2014**.

To be included in the *ADBL*, drug products must be approved by the Minister of Health and undergo the usual review process by the Expert Committee on Drug Evaluation and Therapeutics. The submission requirements for drug reviews are available at https://idbl.ab.bluecross.ca/idbl/PDFS/dbl_sec1_drug.pdf.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations call centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

